Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2023 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting

Clinical data on the compassionate use of B-VEC to treat a RDEB patient, with recurrent cicatrizing conjunctivitis that leads to conjunctival scarring, at the Bascom Palmer Eye Institute PITTSBURGH,...
March 06, 2023 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...
March 02, 2023 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

PITTSBURGH, March 02, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...
February 27, 2023 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

• B-VEC PDUFA date May 19, 2023 • Data from the pivotal Phase 3 (GEM-3) trial of B-VEC for dystrophic epidermolysis bullosa published in the New England Journal of Medicine • Four pipeline clinical...
January 18, 2023 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis

PITTSBURGH, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients...
January 09, 2023 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa

PITTSBURGH, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that on January 5, 2023, the U.S. Food and Drug Administration (FDA) notified the...
December 14, 2022 17:00 ET | Source: Krystal Biotech, Inc.

New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

PITTSBURGH, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients...
December 05, 2022 07:00 ET | Source: Krystal Biotech, Inc.

Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

PITTSBURGH, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced that the company will...
December 01, 2022 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference

PITTSBURGH, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...
November 23, 2022 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference

PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...